Fujitsu tackles 'drug loss' in Japan through accelerating clinical trial digitalisation

Fujitsu announced that it will begin initiatives to attract global clinical trials to Japan and tackle the ‘drug loss’ issue by working with pharmaceutical companies and medical institutions to build a new medical data ecosystem.

In July 2024, Fujitsu formed a strategic partnership with Paradigm Health. Fujitsu’s Healthy Living Platform, and the Fujitsu Kozuchi AI service, Fujitsu and Paradigm will facilitate the collection and processing of data stored at medical institutions and speed up the clinical trial planning process.

Fujitsu will work with Paradigm to develop a new clinical trial data ecosystem that utilizes medical data. Paradigm’s clinical trial platform will be combined with Fujitsu’s operational support expertise and cutting-edge technologies in the area of healthcare and life sciences in Japan. Clinical data, such as medical data and genomic data, will be collected from medical institutions through Fujitsu’s Healthy Living Platform. Fujitsu’s AI service, Fujitsu Kozuchi, will process this data so that it is compliant with the necessary laws and regulations, and it will be provided to Paradigm. In addition, Paradigm will use its clinical trial platform to analyze the data and provide pharmaceutical companies with the insight needed to plan and conduct clinical trials. The aim will be to allow pharmaceutical companies to better understand the situation at the medical institutions as well as the distribution of patients during the planning phase of the clinical trial, and significantly optimize the clinical trial design process.

Medical institutions will also be able to quickly access information about clinical trials in which patients are able to participate through Paradigm’s clinical trial platform, making it easier for medical institutions to encourage patients to participate in clinical trials at the appropriate time.

In addition, Fujitsu will now release patient-centric clinical trials, a new service for automatically creating clinical trial documents using Fujitsu’s proprietary large language model (LLM).Through these efforts, Fujitsu aims to secure 20.0 billion Yen in revenue in fiscal 2030, as well as contribute to achieving a society in which patients can quickly obtain the medicine they need and choose the treatment that best suits them.

Fujitsu will launch these solutions starting in September 2024, beginning with providing support to core clinical research hospitals.